Core Points - The company received notification from the World Health Organization (WHO) regarding the successful closure of the on-site inspection for its active pharmaceutical ingredient, Levonorgestrel (APIMF484, WHOAPI-484) [1] - The inspection results indicate that the company's production line complies with WHO Good Manufacturing Practice (GMP) standards, which is beneficial for maintaining stable product quality and production capacity to meet market demand [1] - The successful WHO pre-certification inspection is not expected to have a significant impact on the company's recent performance [1]